Lupin Plans to Launch Two of its Biosimilars in the US

 Lupin Plans to Launch Two of its Biosimilars in the US

Lupin to Divest its Stake in Kyowa to Unison for ~$525M

Shots:

  • Lupin is planning for EU approval of etanercept biosimilar in Mar 2020 with its expected launch in July 2020 in European markets, further planning its launch in the US and has also received approval in Japan in Mar 2019
  • Additionally, Lupin has also signed an agreement with Mylan to launch its drug in Asia, Australia, Europe, and New Zealand
  • Etanercept is a mAb targeting inflammatory cytokine tumor necrosis factor (TNF) and can be used to treat various forms of arthritis. Lupin also plans to file the approval of etanercept and pegfilgrastim biosimilars in the US in Q4 of the same year

Click here to­ read full press release/ article | Ref: Gabi | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post